Custom Search

News

Monday 01 December 2003

Ziprasidone in Huntington's disease: the first case reports.

By: Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP.

J Psychopharmacol 2003 Dec;17(4):459-60

Huntington's disease (HD) is a relentlessly progressive neuropsychiatric disorder with an underlying autosomal dominantly inherited genetic defect. Classical antipsychotics (i.e. phenothiazines or butyrophenones) are the most used medication to reduce the (probably dopamine-born) choreiform hyperkinesias. Ziprasidone is the latest of a new class of atypical antipsychotics; it has not been studied so far in this indication. We report three genetically confirmed HD patients who improved significantly in several categories of the motor scale of the Unified HD Rating Scale.

Use of this site is subject to the following terms of use